Advertisement
Screener

ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Expense Breakdown

ARCUTIS BIOTHERAPEUTICS, INC. Expense Breakdown

No Expense Breakdown for ARQT on this site yet.

  • 2026-06-30: Reportable $10.38M.
  • 2025-06-30: Reportable $6.93M.

Source checked: the stored Expense Breakdown page for ARQT.

Expenses by product

Cost of sales: each quarter (3 month)

Quarter endReportable
2026-06-30$10.38M
2025-06-30$6.93M

Costs and Expenses: each quarter (3 month)

Quarter endReportable
2026-06-30$113.43M
2025-06-30$96.11M

Income Tax Expense (Benefit): each quarter (3 month)

Quarter endReportable
2026-06-30$136.00K
2025-06-30$342.00K

Selling, General and Administrative Expense: each quarter (3 month)

Quarter endReportable
2026-06-30$82.01M
2025-06-30$69.03M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Arcus Biosciences, Inc. (RCUS)United States$3.188B-8.52
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
AbCellera Biologics Inc. (ABCL)$3.879B-14.59